2.07
+8.38%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Artelo Biosciences
From its filings with the US Securities and Exchange Commission
Artelo Biosciences is based in Solana Beach, California and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker ARTL. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $12.9m. At that date it held total assets of $2.8m and shareholders' equity of −$1.3m.
We incorporated in the State of Nevada on May 2, 2011, and are presently based in the County of San Diego, California. We are a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system (the “ECS”), a network of receptors and neurotransmitters that form a biochemical communication system throughout the body.
Our product candidate pipeline broadly leverages leading scientific methodologies and balances risk across mechanisms of action and stages of development. Our programs represent a comprehensive approach in utilizing the power and promise of lipid signaling to develop pharmaceuticals for patients with unmet healthcare needs.
We are currently developing a novel, benzimidazole dual cannabinoid (CB) agonist that targets both the CB1 and CB2 peripheral receptors. This synthetic small molecule program is a G protein-coupled receptor (“GPCR”) designated ART27.13 and was initially developed by AstraZeneca plc. We are developing ART27.13 as a potential treatment for cancer-related anorexia and it is currently in a Phase 1b/2a trial, titled the Cancer Appetite Recovery Study (“CAReS”). In an interim analysis of the on-going Phase 2a CAReS trial, patients with cancer anorexia receiving ART27.13 demonstrated a mean weight gain of over 6% compared to a 5% loss in the placebo group, while maintaining a safety profile similar to the Phase 1b despite doses up to twice the previous maximum.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 13 Oct 2015
- Employees
- 7
- Website
- artelobio.com ↗
- Head office
- 505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA, 92075
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Connie MatsuiIndependent Chairperson of the Board$88,505
- Mr. Gregory GorgasPresident, Chief Executive Officer, Secretary, Director, since 2017$1.1m
- Mr. Mark SpringChief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer
- Dr. Douglas BlayneyIndependent Director$58,452
- Dr. R. Martin EmanueleIndependent Director$54,136
- Ms. Tamara FavoritoIndependent Director$63,251
- Mr. Steven KellyIndependent Director$70,456
- Dr. Gregory ReyesIndependent Director$50,630
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Artelo Biosciences focuses on endocannabinoid system treatments with three pipeline products.
- The company has a clear pipeline including ART12.11 for IBD and stroke targeting.
- Artelo's products ART26.12 and ART27.13 target cancer and pain conditions effectively.
Weaknesses
- Artelo employs only seven full-time employees, limiting operational capacity.
- The company has a small workforce with only three full-time employees in development.
- Artelo's small team size may hinder rapid development and commercialization efforts.
Opportunities
- The endocannabinoid system market offers growth potential for new treatments.
- Artelo's pipeline includes treatments for rare orphan diseases and cancer.
- Expanding into cachexia treatment could open new market segments.
Threats
- The pharmaceutical industry faces intense competition for endocannabinoid therapies.
- Regulatory challenges may delay approval of cannabinoid-based treatments.
- Market acceptance of cannabinoid therapeutics remains uncertain in the US.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.